University of Pittsburgh Cancer Institute (UPCI)

John M. Kirkwood, MD

John Kirkwood
Co-Leader, Melanoma Program, UPCI
Thomas and Sandra Usher Professor of Medicine, Dermatology and Translational Science

Contact Information

Contact Information

Hillman Cancer Center
UPCI Research Pavilion
5117 Centre Avenue, Suite 1.32
Pittsburgh, PA 15213-1863

Phone: 412-623-3243
Email: kirkwoodjm@upmc.edu
Fax: 412-623-7704

Administrative Assistant
Name: Lisa Huntley
Phone: 412-623-7707
Email: huntleyl@upmc.edu
Fax: 412-623-7704

Research Keywords

Research Keywords

Melanoma; immunology; immunotherapy; interferon; cancer vaccines; clinical trials

Research Summary

Research Summary

The Kirkwood laboratory is engaged in the study of melanoma immunobiology, and the assessment of multipe new immunodulators in the context of trials conducted by the Melanoma Program of the UPCI, and the SPORE in Melanoma and Skin Cancer, as well as the International Melanoma Working Group. The study of predictive and prognostic biomarkers of melanoma complements the studies of molecular inhibitors of melanoma signaling and immunomodulatory agents given alone and in combination with one another.

Selected Publications

Selected Publications

  • Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. PubMed Link
  • Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507-16. PubMed Link
  • Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov;13(11):1087-95. PubMed Link
  • Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20;31(3):373-9. PubMed Link
  • Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10;31(5):616-22. PubMed Link
  • Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20;30(3):322-8. PubMed Link
  • Tarhini AA, Kirkwood JM. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy? J Clin Oncol. 2012 Nov 1;30(31):3773-6. PubMed Link
  • Kaufman HL, Kirkwood JM,et al.The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 Aug 27. PubMed Link
  • Tawbi HA, Kirkwood JM. Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect. Nat Rev Clin Oncol. 2012 Sep;9(9):496-7. PubMed Link
  • Tawbi HA, Kirkwood JM. Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect. Nat Rev Clin Oncol. 2012 Sep;9(9):496-7. PubMed Link

See all pubs (Pubmed)

Collaborations

Collaborations

Current External Collaborators

Bruce Averbook, MD, FACS
Associate Professor
Case Western Reserve University School of Medicine

Michael Davies, MD, PhD
Assistant Professor
The University of Texas MD Anderson Cancer Center

Christine Falk, MD
Professor
Hannover Biomedical Research School

Thomas Gajewski, MD
Professor of Medicine
The University of Chicago Medicine

Jeffrey Gershenwald, MD
Professor (term-tenured),
he University of Texas MD Anderson Cancer Center

Helen Gogas, MD
Associate Professor in Medical Oncology
University of Athens

Grant McArthur, MD
Associate Professor
Peter MacCallum Cancer Centre

Mark Middleton, MD, FCRP
Professor of Experimental Cancer Medicine & Consultant Medical Oncologist
Oxford University Hospitals NHS Trust

Stergios Moschos, MD
Associate Professor
UNC Lineberger Comprehensive Cancer Center

Antonio Ribas, MD, PhD
Professor
UCLA Jonsson Comprehensive Cancer Center

Craig Slingluff, MD
Professor of Surgery
University of Virginia

UPCI Shared Resource Usage

UPCI Shared Resource Usage

  • Biostatistics Facility
  • Cancer Bioinformatics Services
  • Cancer Genomics Facility
  • Cancer Pharmacokinetics and Pharmacodynamics Facility
  • IMCPL
  • Tissue and Research Pathology Services

Affiliated Graduate Programs

Department Website









Last modified: 6/5/14